Every Form 4 that Immuneering Corporation (IMRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IMRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMRX filings page.
Immuneering Corp granted Chief Financial Officer Andrew Gengos stock options covering 650,000 shares of Class A Common Stock at an exercise price of $4.78 per share, expiring July 16, 2036. The options vest monthly over four years under a detailed, step-up vesting schedule tied to continued employment.
Immuneering Corp director and CEO Benjamin J. Zeskind reported buying 2,400 shares of Class A Common Stock in an open-market purchase on June 23, 2026 at a weighted average price of $4.5617 per share, with individual trade prices ranging from $4.55 to $4.59 through a broker-dealer.
After this transaction, he directly owns 2,315,252 shares of Immuneering’s Class A Common Stock. A separate entry shows 894,927 shares held indirectly by the Benjamin J. Zeskind 2020 Family Trust, where his spouse Lisa Schwartz serves as sole trustee.
Immuneering Corp's Chief Scientific Officer Brett Matthew Hall reported an open-market purchase of Class A Common Stock. On June 15, 2026, he bought 6,035 shares at a weighted average price of $4.15 per share. Following this transaction, he directly owns 382,531 shares of Immuneering Corp stock. The filing notes the trade was executed through a broker-dealer in multiple transactions at prices ranging from $4.146 to $4.15 per share, with the reported price representing the weighted average.
Immuneering Corp director Thomas J. Schall received a grant of stock options covering 33,350 shares of Class A common stock at an exercise price of $4.12 per share. The options vest in equal monthly installments over one year starting on July 11, 2026.
The award will be fully vested by June 11, 2027 or on the date of the 2027 annual meeting of stockholders, whichever occurs first. This is a compensation-related equity grant rather than an open-market stock purchase or sale.
Immuneering Corp director Diana Hausman received a grant of stock options covering 33,350 shares of Class A common stock. The options have an exercise price of $4.12 per share and were awarded as compensation, not purchased in the market.
The option grant vests in equal monthly installments over one year starting on July 11, 2026, and will be fully vested by June 11, 2027 or the date of the 2027 annual meeting of stockholders, whichever occurs first. After this grant, she holds options for 33,350 shares directly.
Immuneering Corp director Robert J. Carpenter received a grant of stock options for 33,350 shares of Class A common stock. The options have an exercise price of $4.12 per share and expire on June 11, 2036. They vest in equal monthly installments over one year starting July 11, 2026, becoming fully vested by June 11, 2027 or the 2027 annual stockholder meeting, whichever occurs first. Following this grant, he holds 33,350 stock options directly.
Immuneering Corp director Laurie Keating received a grant of 33,350 stock options. These options allow her to buy Class A common stock at an exercise price of $4.12 per share and are held directly.
The options vest in equal monthly installments over one year starting on July 11, 2026. They will be fully vested and exercisable on June 11, 2027, or on the date of the 2027 annual meeting of stockholders, whichever occurs first. After this grant, Keating holds 33,350 stock options in total.
Immuneering Corp director Peter Feinberg received a grant of stock options covering 33,350 shares of Class A common stock. The options have an exercise price of $4.12 per share and expire on June 11, 2036. They vest in equal monthly installments over one year starting July 11, 2026, becoming fully vested by June 11, 2027 or the 2027 annual stockholder meeting, whichever comes first. Following this grant, Feinberg holds 33,350 stock options directly.
Immuneering Corp’s Chief People Officer, Leah R. Neufeld, acquired additional company stock through an employee plan. She obtained 3,628 shares of Class A Common Stock on the ESPP Purchase Date of March 13, 2026 at $4.2925 per share, under the 2021 Employee Stock Purchase Plan for the offering period from September 16, 2025 through March 15, 2026. The plan price was set at not less than 85% of the fair market value on the purchase date. Following this routine, compensation-related acquisition, Neufeld directly holds 29,598 shares, and the transaction is exempt under Rule 16b-3(c).
Immuneering Corp’s chief legal officer and secretary, Michael Bookman, received a new stock option grant. On February 3, 2026, he was awarded options to purchase 176,000 shares of Class A common stock at an exercise price of $4.91 per share.
The options vest in equal monthly installments over four years starting February 1, 2026, and will be fully vested and exercisable on January 1, 2030. All 176,000 derivative securities are reported as directly owned following this grant.
Immuneering Corp reported that its Chief Business Officer, Harold Eugene Brakewood, received a stock option award covering 140,000 shares of Class A common stock on February 3, 2026. The option has an exercise price of $4.91 per share and is held directly.
The option vests in equal monthly installments over four years, beginning on February 1, 2026, and will be fully vested and exercisable on January 1, 2030. After this grant, Brakewood beneficially owns 140,000 derivative securities linked to Immuneering’s Class A common stock.
Immuneering Corp's chief scientific officer, Brett Matthew Hall, reported a new stock option grant. On February 3, 2026, he was awarded options to purchase 344,000 shares of Class A common stock at an exercise price of $4.91 per share.
The options vest in equal monthly installments over four years, starting February 1, 2026, and are scheduled to be fully vested and exercisable on January 1, 2030. After this grant, Hall beneficially owns 344,000 stock options, all held directly.
Immuneering Corp’s Chief Medical Officer, Igor Matushansky, received a new stock option grant. On February 3, 2026, he was awarded options to acquire 140,000 shares of Class A common stock at an exercise price of $4.91 per share.
The options vest in equal monthly installments over four years starting February 1, 2026 and are scheduled to be fully vested and exercisable on January 1, 2030, aligning long-term compensation with the company’s future performance.
Immuneering Corp executive Mallory Morales, SVP Finance and Chief Accounting Officer, received a grant of stock options covering 140,000 shares of Class A common stock on February 3, 2026. The options have an exercise price of $4.91 per share and were granted at no cost.
The option award vests in equal monthly installments over four years starting February 1, 2026 and will be fully vested and exercisable on January 1, 2030. Following this grant, Morales beneficially owns 140,000 stock options directly.
Immuneering Corp’s chief people officer receives new stock options grant. Leah R. Neufeld was awarded stock options covering 140,000 shares of Class A common stock on February 3, 2026, with an exercise price of $4.91 per share and no purchase price for the options themselves.
The options vest in equal monthly installments over four years starting February 1, 2026, and are scheduled to be fully vested and exercisable on January 1, 2030. Following this grant, Neufeld beneficially owns 140,000 derivative securities directly through this option award.
Immuneering Corp reported that President and CEO Benjamin J. Zeskind received a grant of stock options on February 3, 2026. The award covers 688,000 options with an exercise price of $4.91 per share, each option linked to Class A common stock.
According to the filing, the options vest in equal monthly installments over four years starting on February 1, 2026, and will be fully vested and exercisable by January 1, 2030. Following this grant, Zeskind beneficially owns 688,000 derivative securities directly.
Immuneering Corp’s Chief Business Officer, Harold Eugene Brakewood, reported buying Class A common stock. On January 16, 2026, he purchased 5,250 shares of Immuneering’s Class A common stock at a price of $4.76 per share, coded as an open-market or private purchase (transaction code "P").
After this transaction, Brakewood beneficially owned a total of 11,050 shares of Immuneering Class A common stock, held in direct ownership.
Immuneering Corp director Thomas J. Schall reported buying additional Class A common stock. On January 15, 2026, he purchased 21,645 shares of Immuneering Class A common stock in an open-market transaction coded as a purchase. The weighted average price was $4.6681 per share, with individual trades executed through a broker-dealer at prices ranging from $4.61 to $4.69. Following this transaction, Schall directly beneficially owns 74,530 shares of Immuneering Class A common stock.
Immuneering Corp's Chief Scientific Officer, Brett Matthew Hall, reported buying Class A Common Stock in an insider transaction. On January 15, 2026, he purchased 2,298 shares at a weighted average price of $4.57 per share through a broker-dealer.
After this purchase, Hall directly beneficially owns 376,496 shares of Immuneering Class A Common Stock. The trade was executed in multiple lots at prices ranging from $4.57 to $4.571, with the weighted average price reported in the filing.
Immuneering Corp's Chief People Officer, Leah R. Neufeld, reported buying 2,626 shares of the company's Class A common stock on January 13, 2026. The purchase was recorded at a price of $4.153 per share and is classified as a direct acquisition. After this transaction, Neufeld directly holds 25,970 Class A common shares of Immuneering Corp.
Immuneering Corp director Peter Feinberg reported an indirect purchase of Class A common stock on January 12, 2026. Through S4K Investments LLC, he acquired 20,000 shares at a weighted average price of $4.3452 per share, with individual trade prices ranging from $4.315 to $4.38.
After this transaction, Feinberg beneficially owned 135,441 Class A shares indirectly as general partner of S4K Investments LLC. He also held 156,766 shares directly, plus indirect holdings of 392,242 shares as general partner of PF Associates L.P. and 476,615 shares as general partner of PEF LLC.
Immuneering Corp$6.58 per share, granted on 01/01/2026 and expiring on 01/01/2036.
Under the program, Keating elected to take this stock option instead of a cash base retainer. The option vests in four equal installments: 25% of the shares vest after three months of continuous service as a non-employee director, with the remaining installments vesting so that the final portion vests on the first anniversary of the grant date, as long as service continues. Following this grant, 7,888 derivative securities are beneficially owned directly.
Insider purchase by Director Peter Feinberg. The filing shows a purchase of 7,500 shares of Class A common stock on 10/03/2025 at a reported price of $6.67 per share. After the transaction, Mr. Feinberg directly owns 156,766 shares and indirectly beneficially owns larger stakes through entities: 392,242, 476,615, and 115,441 shares via three general‑partner relationships, bringing total reported beneficial holdings across direct and indirect positions to a material position in the company.
Insider purchase reported: Immuneering Corp (IMRX) Chief Accounting Officer Mallory Morales reported acquiring 300 shares of Class A common stock on 10/01/2025 at a price of $6.39 per share. After the transaction, Morales beneficially owns 27,533 shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025. No derivative transactions or additional remarks were reported in the filing.
Insider transaction reported for Immuneering Corp (IMRX). Leah R. Neufeld, listed as Chief People Officer and reporting person, purchased 800 shares of Class A common stock on 10/01/2025 at a price of $6.3792 per share. After the purchase, the filing reports 23,344 shares beneficially owned. The Form 4 was signed on behalf of Ms. Neufeld by an attorney-in-fact and dated 10/02/2025.
Immuneering Corp (IMRX) Chief Legal Officer and Secretary Michael D. Bookman reported a personal purchase of 1,020 shares of Class A common stock on 10/01/2025 at a price of $6.8299 per share. Following the transaction, Mr. Bookman beneficially owns 4,870 shares. The Form 4 was signed on 10/02/2025 and lists his role as an officer and director. No derivative transactions or additional remarks were reported on the filing.
Insider purchase reported by Immuneering Corp (IMRX) Peter Feinberg, identified as a Director, reported purchasing 7,500 shares of Class A Common Stock on 09/30/2025 at a weighted-average price of $7.0307 per share. After the purchase Feinberg directly beneficially owned 149,266 shares and also reported indirect holdings of 392,242 shares via PF Associates L.P., 476,615 shares via PEF LLC, and 115,441 shares via S4K Investments LLC. The filing notes the purchase was executed in multiple trades at prices from $7.0049 to $7.055. The Form 4 is signed by an attorney-in-fact on 10/01/2025.
Peter Feinberg, a director of Immuneering Corp (IMRX), reported a purchase of 5,000 Class A common shares on 09/29/2025 at a price of $7.18 per share. After the transaction he beneficially owns 141,766 shares directly, plus additional indirect holdings through entities (392,242; 476,615; 115,441), as listed on the Form 4. The filing was signed by an attorney-in-fact on 09/30/2025. This Form 4 discloses an insider purchase that increases the reporting person’s stake but contains no other financial metrics or commentary.